Browse All

Current Filters

CLEAR FILTER x

TITLE

Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials

Author:Filippi, Massimo   Riolo, Jon   Cohen, Jeffrey   Hartung, Hans-Peter   Montalban, Xavier   Meuth, Sven   Freeman, Leorah   Chitnis, Tanuja   Granziera, Cristina   Deboer, Erik   Cheng, Chun-Yen   Reardon, Jennifer   Pachai, Chahin   Sheffield, James   Cree, Bruce   Kappos, Ludwig   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.014  

Author Institution:Neuroimaging Research Unit, Division of Neuroscience, Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy, Milan, Italy  Bristol Myers Squibb, Princeton, New Jersey, USA, Princeton, NJ  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Sydney, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, Duesseldorf, Germany  Dell Medical School, The University of Texas at Austin, Austin, Texas, USA, Austin, TX  Brigham and Women’s Hospital, and Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA, Boston, MA  Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland  Department of Neurology, University Hospital Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Bristol Myers Squibb, Princeton, New Jersey, USA, New York, NY  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA , San Francisco, CA  

Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis

Author:Kieseier, Bernd   Montalban, Xavier   Williams, Mitzi   Airas, Laura   Saini, Sarbjit   Hide, Michihiro   Sussman, Gordon   Nakahara, Jin   Bermel, Robert   Doerner, Thomas   Loop, Brett   DeLasHeras, Virginia   Willi, Roman   Haemmerle, Sibylle   Zharkov, Artem   Barbier, Nathalie   Azmon, Amin   Siegel, Richard   Cenni, Bruno   Wiendl, Heinz   Maurer, Marcus   Gimenez-Arnau, Ana   Chitnis, Tanuja   

Session Name:P8: Multiple Sclerosis: Non-MS CNS Neuroinflammatory Diseases and Progressive MS and Remyelination/Neuroprotection  

Topic:Multiple Sclerosis  

Program Number:P8.015  

Author Institution:Novartis Pharma AG, Basel, Switzerland  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain  Joi Life Wellness Group, Atlanta, GA  Turku University Hospital and University of Turku, Turku, Finland  Johns Hopkins Asthma and Allergy Center, Baltimore, MD  Hiroshima Citizens Hospital, Minami-ku, Japan  University of Toronto, Toronto, ON, Canada  Department of Neurology, Keio University School of Medicine, Tokyo, Japan  Mellen Center for MS, Cleveland Clinic, Cleveland, OH  Department of Rheumatology and Clinical Immunology, Charite – Universitätsmedizin Berlin, Berlin, Germany  Novartis Pharmaceutical Corporation, Cambridge, MA  Novartis Institutes for Biomedical Research, Basel, Switzerland  Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany  Urticaria Center of Reference and Excellence, Institute of Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany  Department of Dermatology, Hospital del Mar – IMIM, Universitat Pompeu Fabra, Barcelona, Spain  Department of Neurology, Brigham and Women's Hospital, Boston, MA  

B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights from ASCLEPIOS I and II Trials

Author:Cross, Anne   Hauser, Stephen   Wiendl, Heinz   Bar-Or, Amit   Coyle, Patricia   Montalban, Xavier   De Seze, Jerome   Fu, Haoyi   Bhatt, Alit   Boer, Ibolya   Kappos, Ludwig   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.002  

Author Institution:Washington University School of Medicine, Saint Louis, MO, USA, Clayton, MO  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  University of Münster, Münster, Germany, Muenster, Germany  Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA, Philadelphia, PA  Department of Neurology, Stony Brook University, Stony Brook, NY, USA, Stony Brook, NY  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Headorgans, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels

Author:Pardo, Gabriel   Kappos, Ludwig   Cross, Anne   Kuhle, Jens   Montalban, Xavier   Khachanova, Natalia   Bhatt, Alit   Piccolo, Rebecca   Xi, Jing   Boer, Ibolya   Arnold, Douglas   Alvarez, Enrique   Ziemssen, Tjalf   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.008  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma City, OK  RC2NB, University Hospital Basel, Basel, Switzerland  Washington University School of Medicine, Clayton, MO  Neurologic Clinic and Policlinic and MS Center, Basel, Switzerland  Vall Hebron University Hospital-Multiple Sclerosis Centre of Catalonia, Barcelona, Spain  Russian National Research Medical University N.I. Pirgov, Moscow, Russian Federation  Novartis Healthcare Pvt. Ltd, Hyderabad, India  Novartis Pharmaceuticals Corporation, West Roxbury, MA  Novartis, Shanghai, China, People's Republic of  Novartis Pharma AG, Basel, Switzerland  Montreal Neurological Institute, McGill Univ, Montreal, QC, Canada  University of Colorado, Aurora, CO  University Clinic Dresden, Dresden, Germany  

The Bruton’s Tyrosine Kinase Inhibitor Remibrutinib Exhibits No Impact on Serum Immunoglobulin Levels: Insights from Chronic Spontaneous Urticaria

Author:Bermel, Robert   Carr, Warner   Chitnis, Tanuja   Dörner, Thomas   Hayama, Koremasa   Hide, Michihiro   Maurer, Marcus   Montalban, Xavier   Sussman, Gordon   Wiendl, Heinz   Dahale, Swapnil   DeLasHeras, Virginia   Haemmerle, Sibylle   Kieseier, Bernd   Lheritier, Karine   Zharkov, Artem   Willi, Roman   Giménez-Arnau, Ana   

Session Name:P10: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 3  

Topic:Multiple Sclerosis  

Program Number:P10.018  

Author Institution:Cleveland Clinic, Cleveland, OH  Allergy and Asthma Associates of Southern California, and Southern California Research, Mission Viejo, CA  Brigham and Women's Hospital, Boston, MA  Charite Universitätsmedizin Berlin, Berlin, Germany  Nihon University School of Medicine, Tokyo, Japan  Hiroshima Citizens Hospital, Minami-ku, Japan  Charité - Universitätsmedizin Berlin, Berlin, Germany  Vall Hebron University Hospital-Multiple Sclerosis Centre of Catalonia, Barcelona, Spain  Gordon Sussman Clinical Research Inc., North York, ON, Canada  University of Muenster, Muenster, Germany  IQVIA, Mumbai, India  Novartis Pharma AG, Basel, Switzerland  Novartis, Basel, Switzerland  Hospital del Mar - IMIM, Universitat Pompeu Fabra, Barcelona, Spain